Craft

Omega Therapeutics

Stock Price

$1.2

2024-10-29

Market Capitalization

$68.4 M

2024-10-29

Revenue

$3.1 M

FY, 2023

Omega Therapeutics Summary

Company Summary

Overview
Omega Therapeutics is an epigenomic medicine company. Its drug development platform is focused on selectively directing the human genome to treat disease by controlling genomic expression without changing nucleic acid sequences. The company develops therapeutics for a range of disease indications, including rare genetic diseases, immunology, inflammation, metabolic diseases, and oncology.
Type
Public
Status
Active
Founded
2017
HQ
Cambridge, MA, US | view all locations
Website
https://omegatherapeutics.com/
Cybersecurity rating
Sectors

Key People

  • Mahesh Karande

    Mahesh Karande, President and CEO, Board Director

  • Thomas McCauley

    Thomas McCauley, Chief Scientific Officer

  • Barbara Chan
  • Qi-Ying Hu

LocationsView all

1 location detected

  • Cambridge, MA HQ

    United States

    20 Acorn Park Dr

Omega Therapeutics Financials

Summary Financials

Revenue (Q3, 2024)
$2.6M
Net income (Q3, 2024)
($16.4M)
Cash (Q3, 2024)
$30.4M
EBIT (Q3, 2024)
($16.4M)
Enterprise value
$53.6M

Footer menu